Abstract: Taxol is a highly oxygenated diterpenoid of broad spectrum anticancer activity, due it unique specificity for binding with tubulin β-subunits heterodimer of tumor cells, disrupting their mitotic division. Taxol has been commercially produced from Taxus brevifolia, however, its lower yield, accessibility and pricey are the current challenges for this technology, thus, exploring of fungi as alternative source of taxol could opened new platforms for production of this drug. From our previous studies, taxol has been produced by A. terreus with the same chemical structural identity with that from T. brevifolia. Thus, the objective of this study was to comparatively evaluate the cytotoxicity and anticancer activity of Aspergillus Terreus taxol (AT-taxol) and commercial Taxus Brevifolia taxol (TB-taxol) against ehrlich ascites carcinoma in female Swiss albino mice via. intraperitoneal injection. Taxol from both sources had the same cytotoxic biochemical patterns as well as anticancer activity against ehrlich ascites carcinoma. Positive control mice showed an increasing on the serum Nitric Oxide (NO) and lipid peroxidation (MDA) level accompanied by a decline in Total Antioxidant Capacity (TAC) in addition to MMP9 upregulation and caspase-3 down regulation. Histopathologically, liver and kidney tissues showed some pathological features due to the oxidative stress induced by EAC. AT-taxol and TB-taxol gave the same potent antioxidant and anticancer properties by augmenting the antioxidant defense system through induction of apoptosis and protecting both liver and kidney against oxidative stress induced by ehrlich ascites carcinoma.